ACE and Duchenne muscular dystrophy: Other investigators found that improvement of vascular function by ACE (Russo et al., 2018) or phosphodiesterase type 5 (Nelson et al., 2014) inhibitors brings along benefit in DMD patients, underlining the pathophysiological importance and potential target of vascular endothelium in DMD-associated cardiovascular abnormalities.